600594.SS
Guizhou Yibai Pharmaceutical Co., Ltd. [600594.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600594.SS Stock Summary
Top 10 Correlated ETFs
600594.SS
Top 10 Correlated Stocks
600594.SS
In the News
600594.SS Financial details
Company Rating
Buy
Market Cap
3.73B
Income
-462.71M
Revenue
2.77B
Book val./share
4.06
Cash/share
0.7
Dividend
-
Dividend %
-
Employees
5.56K
Optionable
No
Shortable
Yes
Earnings
19 Apr 2024
P/E
-9.63
Forward P/E
-
PEG
0.33
P/S
1.61
P/B
1.39
P/C
5.91
P/FCF
-5.69
Quick Ratio
1.44
Current Ratio
2.32
Debt / Equity
0.3
LT Debt / Equity
0.14
-
-
EPS (TTM)
-0.58
EPS next Y
-
EPS next Q
-
EPS this Y
-277.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-9.78%
Revenue last 5Y
-6.77%
Revenue Q/Q
-17.44%
EPS Q/Q
-51.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-16.67%
Inst Own
-
Inst Trans
-
ROA
-9%
ROE
-15%
ROC
-0.11%
Gross Margin
69%
Oper. Margin
-15%
Profit Margin
-17%
Payout
-9%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.8-6.35
52W High
-31%
52W Low
+38%
RSI
36
Rel Volume
1.1
Avg Volume
12.07M
Volume
13.24M
Perf Week
-15.68%
Perf Month
-8.81%
Perf Quarter
-25.27%
Perf Half Y
-28.74%
-
-
-
-
Beta
0.418
-
-
Volatility
0.32%, 0.23%
Prev Close
-2.13%
Price
4.14
Change
3.24%
600594.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.9 | 4.24 | 4.31 | 4.23 | 3.45 | |
| Net income per share | -0.92 | 0.18 | 0.29 | 0.31 | -0.55 | |
| Operating cash flow per share | 0.27 | 0.46 | 0.46 | 1.18 | 0.44 | |
| Free cash flow per share | -0.14 | 0.2 | -0.04 | 0.61 | 0.03 | |
| Cash per share | 0.45 | 1.09 | 0.56 | 0.26 | 0.75 | |
| Book value per share | 4.36 | 4.55 | 4.25 | 4.42 | 3.84 | |
| Tangible book value per share | 3.39 | 3.23 | 3.14 | 3.04 | 3.36 | |
| Share holders equity per share | 4.36 | 4.55 | 4.25 | 4.42 | 3.84 | |
| Interest debt per share | 2 | 1.76 | 1.55 | 1.18 | 1.41 | |
| Market cap | 4.32B | 3.94B | 4.13B | 6.44B | 4.38B | |
| Enterprise value | 5.28B | 4.26B | 4.7B | 6.96B | 4.86B | |
| P/E ratio | -5.96 | 27.79 | 18.07 | 26.41 | -9.99 | |
| Price to sales ratio | 1.11 | 1.17 | 1.21 | 1.92 | 1.6 | |
| POCF ratio | 20.18 | 10.87 | 11.27 | 6.89 | 12.68 | |
| PFCF ratio | -40.4 | 24.43 | -142.15 | 13.24 | 195.73 | |
| P/B Ratio | 1.25 | 1.1 | 1.23 | 1.84 | 1.44 | |
| PTB ratio | 1.25 | 1.1 | 1.23 | 1.84 | 1.44 | |
| EV to sales | 1.36 | 1.27 | 1.38 | 2.08 | 1.78 | |
| Enterprise value over EBITDA | 9.88 | 8.04 | 7.49 | 10.15 | 11.09 | |
| EV to operating cash flow | 24.65 | 11.75 | 12.82 | 7.45 | 14.09 | |
| EV to free cash flow | -49.36 | 26.4 | -161.66 | 14.31 | 217.42 | |
| Earnings yield | -0.17 | 0.04 | 0.06 | 0.04 | -0.1 | |
| Free cash flow yield | -0.02 | 0.04 | -0.01 | 0.08 | 0.01 | |
| Debt to equity | 0.44 | 0.37 | 0.35 | 0.26 | 0.35 | |
| Debt to assets | 0.23 | 0.24 | 0.23 | 0.18 | 0.22 | |
| Net debt to EBITDA | 1.79 | 0.6 | 0.9 | 0.76 | 1.11 | |
| Current ratio | 1.57 | 2.54 | 1.49 | 1.59 | 1.74 | |
| Interest coverage | -10.64 | 7.34 | 11.79 | 15.26 | 6.87 | |
| Income quality | -0.31 | 2.74 | 1.73 | 4.05 | -0.79 | |
| Dividend Yield | 0.03 | 0.02 | 0.13 | 0.02 | 0.01 | |
| Payout ratio | -0.18 | 0.46 | 2.4 | 0.62 | -0.11 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | |
| Research and developement to revenue | 0.02 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Intangibles to total assets | 0.19 | 0.21 | 0.19 | 0.23 | 0.11 | |
| Capex to operating cash flow | -1.5 | -0.55 | -1.08 | -0.48 | -0.94 | |
| Capex to revenue | -0.08 | -0.06 | -0.12 | -0.13 | -0.12 | |
| Capex to depreciation | -1.79 | -1.32 | -2.81 | -2.99 | -1.78 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.01 | |
| Graham number | 9.48 | 4.28 | 5.26 | 5.54 | 6.92 | |
| ROIC | -0.14 | 0.05 | 0.08 | 0.09 | 0.07 | |
| Return on tangible assets | -0.14 | 0.03 | 0.05 | 0.06 | -0.1 | |
| Graham Net | -0.47 | 0.18 | -0.39 | -0.58 | -0.22 | |
| Working capital | 1.14B | 1.65B | 748.12M | 640.59M | 867.92M | |
| Tangible asset value | 2.68B | 2.56B | 2.49B | 2.41B | 2.66B | |
| Net current asset value | 556.02M | 827.08M | 520.92M | 214.4M | 364.75M | |
| Invested capital | 0.44 | 0.37 | 0.35 | 0.26 | 0.35 | |
| Average receivables | 1.72B | 1.75B | 1.15B | 884.2M | 771.65M | |
| Average payables | 222.69M | 166.02M | 123.52M | 124.45M | 145.18M | |
| Average inventory | 345.72M | 384.75M | 454.46M | 526.5M | 589.86M | |
| Days sales outstanding | 207.85 | 139.83 | 108.83 | 81.88 | 105.76 | |
| Days payables outstanding | 65.47 | 69.01 | 55.72 | 72.35 | 68.67 | |
| Days of inventory on hand | 121.78 | 203.71 | 257.18 | 284.7 | 287.27 | |
| Receivables turnover | 1.76 | 2.61 | 3.35 | 4.46 | 3.45 | |
| Payables turnover | 5.58 | 5.29 | 6.55 | 5.05 | 5.32 | |
| Inventory turnover | 3 | 1.79 | 1.42 | 1.28 | 1.27 | |
| ROE | -0.21 | 0.04 | 0.07 | 0.07 | -0.14 | |
| Capex per share | -0.41 | -0.25 | -0.5 | -0.57 | -0.41 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.83 | 0.8 | 0.86 | 1.01 | 0.83 | |
| Net income per share | 0.09 | -0.8 | 0.06 | 0.11 | 0.05 | |
| Operating cash flow per share | 0.09 | -0.8 | 0.06 | 0.18 | 0.18 | |
| Free cash flow per share | 0.03 | -0.92 | 0.02 | 0.13 | 0.14 | |
| Cash per share | 1.15 | 0.75 | 0.86 | 0.68 | 0.7 | |
| Book value per share | 4.64 | 3.84 | 3.9 | 4.01 | 4.06 | |
| Tangible book value per share | 3.39 | 3.36 | 3.42 | 3.53 | 3.58 | |
| Share holders equity per share | 4.64 | 3.84 | 3.9 | 4.01 | 4.06 | |
| Interest debt per share | 1.74 | 1.38 | 1.49 | 1.42 | 1.25 | |
| Market cap | 3.99B | 4.38B | 4.54B | 4.17B | 4.59B | |
| Enterprise value | 4.45B | 4.86B | 5.04B | 4.62B | 4.89B | |
| P/E ratio | 14.42 | -1.73 | 25.78 | 12.43 | 27.36 | |
| Price to sales ratio | 6.11 | 6.89 | 6.64 | 5.24 | 6.99 | |
| POCF ratio | 57.67 | -6.92 | 103.13 | 29.08 | 32.52 | |
| PFCF ratio | 188.52 | -6.04 | 381.34 | 40.87 | 41.08 | |
| P/B Ratio | 1.09 | 1.44 | 1.47 | 1.32 | 1.43 | |
| PTB ratio | 1.09 | 1.44 | 1.47 | 1.32 | 1.43 | |
| EV to sales | 6.81 | 7.65 | 7.36 | 5.8 | 7.44 | |
| Enterprise value over EBITDA | 64.92 | 202.46 | 76.59 | 41 | 85.24 | |
| EV to operating cash flow | 64.33 | -7.69 | 114.43 | 32.18 | 34.6 | |
| EV to free cash flow | 210.27 | -6.71 | 423.14 | 45.22 | 43.71 | |
| Earnings yield | 0.02 | -0.14 | 0.01 | 0.02 | 0.01 | |
| Free cash flow yield | 0.01 | -0.17 | 0 | 0.02 | 0.02 | |
| Debt to equity | 0.37 | 0.35 | 0.38 | 0.35 | 0.3 | |
| Debt to assets | 0.23 | 0.22 | 0.24 | 0.22 | 0.2 | |
| Net debt to EBITDA | 6.72 | 20.2 | 7.56 | 3.94 | 5.13 | |
| Current ratio | 1.57 | 1.74 | 1.77 | 1.89 | 2.32 | |
| Interest coverage | 6.55 | -48.23 | 113.11 | 23.49 | 4.54 | |
| Income quality | 1 | 1 | 1 | 1.71 | 3.37 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.19 | -0.02 | 0.27 | 0.12 | 0.23 | |
| Sales general and administrative to revenue | 0.27 | -0.13 | 0.11 | 0 | 0.27 | |
| Research and developement to revenue | 0.04 | 0.08 | 0.03 | 0.03 | 0.04 | |
| Intangibles to total assets | 0.19 | 0.11 | 0.11 | 0.1 | 0.1 | |
| Capex to operating cash flow | -0.69 | 0.15 | -0.73 | -0.29 | -0.21 | |
| Capex to revenue | -0.07 | -0.15 | -0.05 | -0.05 | -0.04 | |
| Capex to depreciation | -0.73 | -1.4 | -0.56 | -0.72 | 0.29 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.02 | 8.31 | 2.21 | 3.09 | 2.2 | |
| ROIC | 0.01 | -0.15 | 0.01 | 0.02 | 0.01 | |
| Return on tangible assets | 0.01 | -0.15 | 0.01 | 0.02 | 0.01 | |
| Graham Net | -0.19 | -0.22 | -0.16 | -0.28 | -0.11 | |
| Working capital | 887.86M | 867.92M | 935.42M | 1.04B | 1.21B | |
| Tangible asset value | 2.68B | 2.66B | 2.71B | 2.79B | 2.84B | |
| Net current asset value | 407M | 364.75M | 417.71M | 516.83M | 587.34M | |
| Invested capital | 0.37 | 0.35 | 0.38 | 0.35 | 0.3 | |
| Average receivables | 934.14M | 858.91M | 806.98M | 821.54M | 798.78M | |
| Average payables | 153.7M | 149.68M | 150.45M | 146.23M | 158.93M | |
| Average inventory | 594.69M | 609.85M | 624.27M | 626.48M | 641.94M | |
| Days sales outstanding | 127.49 | 112.15 | 108.11 | 92.92 | 106.26 | |
| Days payables outstanding | 72.98 | 58.44 | 62.31 | 61.35 | 78.72 | |
| Days of inventory on hand | 289.42 | 244.46 | 256.5 | 273.88 | 291.28 | |
| Receivables turnover | 0.71 | 0.8 | 0.83 | 0.97 | 0.85 | |
| Payables turnover | 1.23 | 1.54 | 1.44 | 1.47 | 1.14 | |
| Inventory turnover | 0.31 | 0.37 | 0.35 | 0.33 | 0.31 | |
| ROE | 0.02 | -0.21 | 0.01 | 0.03 | 0.01 | |
| Capex per share | -0.06 | -0.12 | -0.04 | -0.05 | -0.04 |
600594.SS Frequently Asked Questions
What is Guizhou Yibai Pharmaceutical Co., Ltd. stock symbol ?
Guizhou Yibai Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 600594.SS
What is Guizhou Yibai Pharmaceutical Co., Ltd. stock quote today ?
Guizhou Yibai Pharmaceutical Co., Ltd. stock price is $4.14 today.
Is Guizhou Yibai Pharmaceutical Co., Ltd. stock public?
Yes, Guizhou Yibai Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 12.07M
- Market Capitalization 3.73B
- Employee 5.56K
- CEO Ms. Ya Qi Dou
- Headquarters Guiyang,CN
- IPO Date 2004-03-23
-
Website
https://www.gzcci.com 
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.
